Dual inhibition of MEK and mTOR effectively protects against FBXL6- and KRASG12D-triggered hepatocarcinogenesis and lung metastasis, providing a potential strategy to treat this aggressive subtype of liver cancer. Here, MTOR is linked to liver cancer.